AKBA Q3 2021 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M-18.7% YoY

Gross Profit

$33M67.3% margin

Operating Income

-$55M-112.6% margin

Net Income

-$60M-122.1% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-7.9%

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$56M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$602M

Total Liabilities

$465M

Stockholders' Equity

$137M

Cash & Equivalents

$207M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$60M	-18.7%
Gross Profit	$33M	$30M	+10.7%
Operating Income	-$55M	-$58M	+5.5%
Net Income	-$60M	-$60M	+0.7%

Revenue Segments

Product

$37M75%

License Collaboration And Other Revenue

$12M25%